• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

RFA joins arsenal for breast cancer metastases in the liver

Article

In patients for whom surgery is not an option, percutaneous radio-frequency ablation offers a viable alternative for treating breast cancer metastatic disease in the liver.

In patients for whom surgery is not an option, percutaneous radio-frequency ablation offers a viable alternative for treating breast cancer metastatic disease in the liver.

Researchers from 12 centers participating in the tumor radio-frequency ablation Italian network (TRAIN) treated 102 patients with breast cancer, using the ablation technique. Under ultrasound or CT guidance, they applied RFA to tumors ranging from 0.8 to 5 cm in diameter. Results were presented at the 2004 RSNA meeting.

Using the Kaplan-Meier method, the researchers reported survival rates ranging from 95.2% at one year to 29.8% at five years. They completed RFA of tumors in 91.2% of the patients after 121 treatment sessions, and the primary effectiveness rate on a lesion-by-lesion basis was 86.9.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.